Why Israel?

For decades, global pharmaceutical companies have regularly conducted multinational clinical trials
in Israel, and choose GCP to manage their clinical studies. According to the NIH clinical trials register,
more than 2% of registered studies worldwide are conducted in Israel. This is more than all studies
conducted in either Russia, India, Japan or many European countries.

Why?

In 1999 the Israeli government made the timely decision to join as one of the first countries to accept the International Conference on Harmonization (ICH) guidelines for Good Clinical Practice, which were established in 1997. Israel’s early adoption of these standards was a key factor in attracting an increased number of overseas trials to the country.

Israel’s medical infrastructure is extremely advanced and all public medical institutions are active in clinical research and have the state-of-the-art equipment to support clinical studies. Because research staff at Israeli medical institutions have so much clinical study experience, the data coming from Israeli sites is considered of very high quality.

Number of
clinical studies in Israel

  • Drugs
  • Medical Devices
  • Genetic
  • Without IP
  • Questionnaires
  • Advanced Therapies
Both Israel’s institutional and private medical systems are supervised by the Ministry of Health, which is inherently committed to advancing research making regulatory approvals relatively fast and predictable.

There are many, many other reasons Israel is such an attractive clinical study site. Here are just a few more:
GCP_CRO_Why_Israel_icon_
Most Israeli Investigators and research staff have completed GCP courses, required by the Ministry of Health, many of which were delivered by our GCP Academy instructors.

Immigrants from diverse ethnic origins supplying populations of interest for many clinical studies.

Easy tracking and follow up of trial subjects. Israel is known for having highly “evaluable” subjects, easily monitored from start to end thanks to the computerized national public health system. 

Dropout rates, due to subjects lost to follow up, are very low in Israel compared to the US. As a result, companies need to recruit less subjects to get the same quantity of data that would come from larger, and more expensive recruitments elsewhere.

Another factor is that Israel’s government is behind a national initiative to promote Digital Health, investing significant funds in a wide range of programs. This program recognizes the value of the vast amount of medical data
accumulated by the national health system to medical research.

Close Menu